Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial

NCT02926222 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT02926222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
June 30, 2021
Enrollment
119 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme